Randomized Controlled Trial of Cetuximab Plus Chemotherapy for Patients With <i>KRAS</i> Wild-Type Unresectable Colorectal Liver-Limited Metastases

Abstract

For patients with initially unresectable KRAS wild-type CLMs, cetuximab combined with chemotherapy improved the resectability of liver metastases and improved response rates and survival compared with chemotherapy alone.